Liver Cirrhosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Liver Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.
The Liver Cirrhosis – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects.
Key Targets in the Liver Cirrhosis Pipeline Drugs Market
The key targets in the Liver Cirrhosis pipeline drugs market are Catenin Beta 1, Galectin 3, Androgen Receptor, DNA Gyrase, Galectin 1, Interleukin 20, and Klotho among others.
Liver Cirrhosis Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Liver Cirrhosis Pipeline Drugs Market
The key mechanisms of action in the Liver Cirrhosis pipeline drugs market are Catenin Beta 1 Inhibitor, Galectin 3 Inhibitor, Androgen Receptor Agonist, DNA Gyrase Inhibitor, Galectin 1 Inhibitor, Interleukin 20 Inhibitor, and Klotho Activator.
Liver Cirrhosis Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
Liver Cirrhosis Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Liver Cirrhosis pipeline drugs market are Subcutaneous, Intravenous, Oral, Topical, Intravenous Drip, Vaginal, and Parenteral among others.
Liver Cirrhosis Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Liver Cirrhosis Pipeline Drugs Market
The key molecule types in the Liver Cirrhosis pipeline drugs market are Peptide, Small Molecule, Recombinant Protein, Fusion Protein, Cell Therapy, Gene Therapy, and Monoclonal Antibody among others.
Liver Cirrhosis Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the Liver Cirrhosis Pipeline Drugs Market
The major companies in the Liver Cirrhosis pipeline drugs market are PrimeGen Global Inc, Bristol-Myers Squibb Co, Pharmicell Co Ltd, PRISM Pharma Co Ltd Hepion Pharmaceuticals Inc, Innovent Biologics Inc, International Stem Cell Corp, INVENT Pharmaceuticals Inc, Laekna Therapeutics Shanghai Co Ltd, and LBL Biotech Corp, among others.
Liver Cirrhosis Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Liver Cirrhosis Pipeline Drugs Market Overview
| Key Targets | Catenin Beta 1, Galectin 3, Androgen Receptor, DNA Gyrase, Galectin 1, Interleukin 20, and Klotho |
| Key Mechanisms of action | Catenin Beta 1 Inhibitor, Galectin 3 Inhibitor, Androgen Receptor Agonist, DNA Gyrase Inhibitor, Galectin 1 Inhibitor, Interleukin 20 Inhibitor, and Klotho Activator |
| Key Routes of Administration | Subcutaneous, Intravenous, Oral, Topical, Intravenous Drip, Vaginal, and Parenteral |
| Key molecule types | Peptide, Small Molecule, Recombinant Protein, Fusion Protein, Cell Therapy, Gene Therapy, and Monoclonal Antibody |
| Major companies | PrimeGen Global Inc, Bristol-Myers Squibb Co, Pharmicell Co Ltd, PRISM Pharma Co Ltd Hepion Pharmaceuticals Inc, Innovent Biologics Inc, International Stem Cell Corp, INVENT Pharmaceuticals Inc, Laekna Therapeutics Shanghai Co Ltd, and LBL Biotech Corp |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cirrhosis
- The pipeline guide reviews pipeline therapeutics for Liver Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liver Cirrhosis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liver Cirrhosis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Liver Cirrhosis
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liver Cirrhosis
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Alliancells Bioscience Corporation Ltd
Baylx Inc
Bristol-Myers Squibb Co
Candel Therapeutics Inc
CAR-T (Shanghai) Biotechnology Co Ltd
CellionBioMed Inc
China Immunotech Co Ltd
cStem Regeneration Pharmaceutical Co Ltd
D&D Pharmatech Co Ltd
Elixirgen Therapeutics Inc
Galectin Therapeutics Inc
Galecto Inc
Grifols SA
Gwoxi Stem Cell Applied Technology Co Ltd
Hepion Pharmaceuticals Inc
Innovent Biologics Inc
International Stem Cell Corp
INVENT Pharmaceuticals Inc
Laekna Therapeutics Shanghai Co Ltd
LBL Biotech Corp
Lipocine Inc
Mina Therapeutics Ltd
NGM Biopharmaceuticals Inc
Novo Nordisk AS
Ochre Bio Ltd
Oncocross Co Ltd
Pharmicell Co Ltd
PrimeGen Global Inc
PRISM Pharma Co Ltd
Promethera Biosciences SA
Protgen Ltd
Resolution Therapeutics Ltd
Rohto Pharmaceutical Co Ltd
Shanghai Huicun Medical Technology Co Ltd
Shionogi & Co Ltd
Surrozen Inc
TenNor Therapeutics Ltd
Therabest Co Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
Tuohua Biological Technology Co Ltd
Versantis AG
VESSL Therapeutics Ltd
Xfibra Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Liver Cirrhosis pipeline drugs market?
The key targets in the Liver Cirrhosis pipeline drugs market are Catenin Beta 1, Galectin 3, Androgen Receptor, DNA Gyrase, Galectin 1, Interleukin 20, and Klotho.
-
What are the key mechanisms of action in the Liver Cirrhosis pipeline drugs market?
The key mechanisms of action in the Liver Cirrhosis pipeline drugs market are Catenin Beta 1 Inhibitor, Galectin 3 Inhibitor, Androgen Receptor Agonist, DNA Gyrase Inhibitor, Galectin 1 Inhibitor, Interleukin 20 Inhibitor, and Klotho Activator.
-
What are the key routes of administration in the Liver Cirrhosis pipeline drugs market?
The key routes of administration in the Liver Cirrhosis pipeline drugs market are Subcutaneous, Intravenous, Oral, Topical, Intravenous Drip, Vaginal, and Parenteral.
-
What are the key molecule types in the Liver Cirrhosis pipeline drugs market?
The key molecule types in the Liver Cirrhosis pipeline drugs market are Peptide, Small Molecule, Recombinant Protein, Fusion Protein, Cell Therapy, Gene Therapy, and Monoclonal Antibody.
-
What are the major companies in the Liver Cirrhosis pipeline drugs market?
The major companies in the Liver Cirrhosis pipeline drugs market are PrimeGen Global Inc, Bristol-Myers Squibb Co, Pharmicell Co Ltd, PRISM Pharma Co Ltd Hepion Pharmaceuticals Inc, Innovent Biologics Inc, International Stem Cell Corp, INVENT Pharmaceuticals Inc, Laekna Therapeutics Shanghai Co Ltd, and LBL Biotech Corp.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Gastrointestinal reports